Literature DB >> 7214025

Rapid destruction of newly synthesized excess beta-globin chains in HbH disease.

G B Sancar, M M Cedeno, R F Rieder.   

Abstract

A subject with HbG Philadelphia-HbH disease exhibited an unusually high alpha/beta synthesis ratio; when peripheral blood was tested in vitro on several occasions, ratios of 0.63 - 0.89 were obtained after incubations of 30-120 min. HbH amounted to 5%-8% of the circulating hemoglobin. Rapid destruction of excess newly synthesized beta-globin was demonstrated in kinetic and pulse-chase experiments. After 2 min of incubation, the alpha/beta synthesis ratio was 0.48; this figure rose to 0.89 by 30 min. The zero time alpha/beta ratio was estimated to be 0.35. The degradation of beta-chains was calculated to proceed at approximately one-half the rate of beta-globin synthesis; this result was confirmed by the loss of 50% of the specific activity in beta-chains during 9 min of a chase experiment following a 10-min radioactive pulse. The results suggest that efficient proteolysis may be responsible, in some blacks, for the low levels of excess beta-globin chains in HbH disease as well as for the mildness of the clinical disorder.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7214025

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Hemoglobin H disease in Muscat, Oman - A 5 year study.

Authors:  Suresh Venugopal; Suchata Dhuri; Khalid Bait Al Jabal; Alphonsa Shaju
Journal:  Oman Med J       Date:  2008-04

Review 2.  Protein quality control during erythropoiesis and hemoglobin synthesis.

Authors:  Eugene Khandros; Mitchell J Weiss
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

3.  Hemoglobin Mississippi (beta 44ser----cys). Studies of the thalassemic phenotype in a mixed heterozygote with beta +-thalassemia.

Authors:  M H Steinberg; J G Adams; W T Morrison; D J Pullen; R Abney; A Ibrahim; R F Rieder
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

4.  βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid Cells.

Authors:  Selami Demirci; Bjorg Gudmundsdottir; Quan Li; Juan J Haro-Mora; Tina Nassehi; Claire Drysdale; Morgan Yapundich; Jackson Gamer; Fayaz Seifuddin; John F Tisdale; Naoya Uchida
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-18       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.